Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Post by prophetoffactzon Jul 30, 2024 9:04am
93 Views
Post# 36154055

3.7 million

3.7 millionStockhouse has update the AEZS shares outstanding to 3.7 million. That likely includes the warrants that were issued to AEZS holders immediately before the merger closed.

That's a C$28 million market cap at C$7.6.

$28 million market cap would be C$.36 per CZO before the merger. 

H.C. Wainwright had a C$100 million market cap target for AEZS before the merger and that was set before a big rally in biotech. 

C$100 million market cap with 3.7 million shares is C$27 per AEZS shares and that ignores the merger of equals potentially doubling the value and that H.C. Wainwright's target was set before a huge surge in biotech shares.
<< Previous
Bullboard Posts
Next >>